Sana Biotechnology, Inc. (SANA) fair value analysis
Nasdaq · Updated 2026-10-19
SANA price how computed
Valuation status
No fair-value estimate yetSANA has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for SANA yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $2.27
- Sector
- Healthcare
- 12-month range
- $2.27–$5.59
- Market cap
- $835M
- From 52-week high
- -59.4%
- Shares outstanding
- 368M
- Rank in Healthcare by quality score
- #297 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Sana Biotechnology, Inc. is a clinical-stage biopharmaceutical company that develops cell and gene therapies to treat diseases including cancer, diabetes, and hemophilia. The company is headquartered in the United States and operates in the healthcare sector as a publicly listed company on the Nasdaq exchange.
SANA currently ranks #297 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $835M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-0.58
- Debt / equity
- 0.48
- Shares outstanding
- 368M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 25 · oversold
- 50-day average
- $3.29
- 200-day average
- $3.49
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 5 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+13.3%)
2026-03 ▲ beat (+6.7%)
2025-12 ▼ miss (-10.8%)
2025-09 ▲ beat (+21.1%)
2025-06 ▲ beat (+23.8%)
2025-03 ▬ met (0.0%)
2024-12 ▲ beat (+5.3%)
2024-09 ▬ met (0.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Consensus price target
- $8.43
- Target vs last price
- +271.4%
What our data shows for SANA
- Shares are trading in the lower third of their 12-month price range of $2.27–$5.59.
- The 14-day relative strength index sits at an oversold 25.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- SANA's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the SANA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — SANA's relative strength index moved into oversold territory this week, shifting from a neutral zone reading in the prior week. The Healthcare sector stock's derived indicators are currently under review as the company awaits a full valuation assessment.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — SANA's Relative Strength Index moved from oversold territory into neutral zone this week, indicating a shift in momentum for the Healthcare sector company. The stock's current valuation verdict remains awaiting full valuation as TickrTrends continues to assess pricing metrics.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is SANA stock undervalued?
TickrTrends has no fair-value estimate for SANA yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is SANA's TickrTrends verdict?
SANA is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does SANA compare to other Healthcare stocks?
SANA ranks #297 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is SANA overbought or oversold?
SANA's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does SANA report earnings next?
SANA's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does SANA usually beat earnings estimates?
Over its last 8 reported quarters SANA beat the consensus estimate 5 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.